Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 4
2011 3
2012 9
2013 10
2014 5
2017 1
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Predictors of consent to pharmacogenomics testing in the IDEAL study.
Jazwinski AB, Clark PJ, Thompson AJ, Gordon SC, Lawitz EJ, Noviello S, Brass CA, Pedicone LD, Albrecht JK, Sulkowski MS, Muir AJ. Jazwinski AB, et al. Among authors: pedicone ld. Pharmacogenet Genomics. 2013 Nov;23(11):619-23. doi: 10.1097/FPC.0000000000000002. Pharmacogenet Genomics. 2013. PMID: 24061202 Free PMC article. Clinical Trial.
High sustained virologic response rates, regardless of race or socioeconomic class, in patients treated with chronic hepatitis C in community practice using a specialized pharmacy team.
Kuwelker S, Tsai E, Kuo L, Kim J, Van Frank T, Mitchell R, Ramirez R, Guerrero R, Hanysak B, Landaverde C, Rodas F, Lawitz E, Basra T, Nguyen H, Christensen K, Vaughn C, Hinojosa K, Olvera N, Caraballo-Gonzalez E, Pham E, Pedicone LD, Poordad F. Kuwelker S, et al. Among authors: pedicone ld. Medicine (Baltimore). 2023 Jul 28;102(30):e34183. doi: 10.1097/MD.0000000000034183. Medicine (Baltimore). 2023. PMID: 37505173 Free PMC article.
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.
Thompson AJ, Clark PJ, Singh A, Ge D, Fellay J, Zhu M, Zhu Q, Urban TJ, Patel K, Tillmann HL, Naggie S, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, King JW, Kwo PY, Shianna KV, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, Goldstein DB, McHutchison JG, Muir AJ. Thompson AJ, et al. Among authors: pedicone ld. J Hepatol. 2012 Feb;56(2):313-9. doi: 10.1016/j.jhep.2011.04.021. Epub 2011 May 20. J Hepatol. 2012. PMID: 21703177 Free PMC article.
Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance.
Loo N, Hanysak B, Mann J, Ramirez R, Kim J, Mitchell R, Van Frank T, Guerrero R, Hinojosa K, Christensen K, Pedicone LD, Alkhouri N, Wells J, Landaverde C, Rodas F, Lawitz E, Poordad F. Loo N, et al. Among authors: pedicone ld. Medicine (Baltimore). 2019 Jun;98(26):e16254. doi: 10.1097/MD.0000000000016254. Medicine (Baltimore). 2019. PMID: 31261592 Free PMC article.
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, Poordad F, Bacon B, Gottesdiener K, Pedicone LD, Albrecht JK, Brass CA, Thompson S, Burroughs MH. Bruno S, et al. Among authors: pedicone ld. J Hepatol. 2013 Mar;58(3):479-87. doi: 10.1016/j.jhep.2012.11.020. Epub 2012 Nov 23. J Hepatol. 2013. PMID: 23183529 Clinical Trial.
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.
Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM; SPRINT-2 Trial Investigators. Sulkowski MS, et al. Among authors: pedicone ld. Hepatology. 2013 Mar;57(3):974-84. doi: 10.1002/hep.26096. Epub 2013 Feb 11. Hepatology. 2013. PMID: 23081753 Clinical Trial.
Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study.
Melia MT, Bräu N, Poordad F, Lawitz EJ, Shiffman ML, McHutchison JG, Muir AJ, Galler GW, Nyberg LM, Lee WM, Schiff E, Long J, Noviello S, Brass CA, Pedicone LD, Sulkowski MS. Melia MT, et al. Among authors: pedicone ld. Clin Infect Dis. 2014 Apr;58(7):960-9. doi: 10.1093/cid/ciu009. Epub 2014 Jan 6. Clin Infect Dis. 2014. PMID: 24399086 Free PMC article. Clinical Trial.
30 results